COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 12 FDA records to the applicant name LivaNova USA, Inc.. The collection includes 1 510(k) clearance. It includes 2 original PMA approvals. 6 entries are PMA supplements. 3 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Jul 16, 1997 to Oct 2, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code LYJ appears in 8 of the 12 linked filings. The collection spans 3 FDA product codes and 2 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P970003, with 8 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 1 linked filing has a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: 100 Cyberonics Blvd., Houston, TX, 77058. Recorded on P970003/S254, decision dated Oct 2, 2026.
Device categories in this collection
Stimulator, Autonomic Nerve, Implanted For Epilepsy; Stimulator, Hypoglossal Nerve, Implanted, Apnea; Catheter, Cannula And Tubing, Vascular, Cardiopulmonary Bypass.
Changes described in PMA records
FDA supplement P970003/S254 records an approval for a change in the battery voltage offset used in the battery longevity calculation for the VNS Therapy System. The offset is to be applied over 15% of battery usage instead of the previous 7.5%.
The supplement is classified as a Real-Time Process for a change in design, components, specifications, or material. The applicant is LivaNova USA, Inc., and the device category is an implanted autonomic nerve stimulator for epilepsy. The decision statement does not describe clinical testing, safety outcomes, or effectiveness data.
FDA approval-order wording
approval for change in the battery voltage offset in battery longevity calculation to be applied over 15% of battery usage instead of 7.5%.
Oct 2, 2026 · Real-Time ProcessFDA’s recorded scope: approval for 1) changing the term partial onset seizures to focal onset seizures in the Indications for Use, 2) changing the term sudden unexplained death to sudden unexpected death, 3) removing the Warning label associated with SUDEP-related information and moving the SUDEP-related information from the Warnings section to the Clinical Studies section of the Physicians Manual, 4) aligning the SUDEP-related information in the Patient Guide with the Physicians Manual and removing the Caution label associated with SUDEP-related information.
Aug 12, 2026 · Normal 180 Day TrackFDA’s recorded scope: approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P250013
Jun 18, 2026 · Normal 180 Day Track No User FeeFDA’s recorded scope: Approval of the protocol for the New Enrollment post-approval study (PAS) submitted to comply with the conditions of approval outlined in our approval order for P250013
Apr 30, 2026 · Normal 180 Day Track No User FeeFDA’s recorded scope: Approval for the aura6000 system, which includes the Implantable Pulse Generator Model #100.0100, Lead Models #300.0100 (25cm) and #300.0200 (33cm), Remote Control & Charger Model #500.0100, Charging Antenna Model #500.0300, aura Clinical Manager Model #700.0100, Torque Wrench, and Suture Sleeve. The device is indicated for the reduction of apneas, hypopneas, or both in adult patients with moderate to severe obstructive sleep apnea (OSA), defined as an apnea-hypopnea index (AHI) of = 15 and = 65. The aura6000 system is intended for patients who failed, do not tolerate, or are ineligible to be treated with current standard of care treatments such as positive airway pressure (PAP), oral appliances (e.g. mandibular advancement device), or pharmacotherapy. PAP failure is defined as an inability to eliminate OSA (AHI of greater than 15 despite PAP usage), and PAP intolerance is defined as: Inability to use PAP (greater than 5 nights per week of usage; usage defined as greater than 4 hours of use per night), or Unwillingness to use PAP (e.g., a patient returns the PAP system after attempting to use it).
Mar 18, 2026Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.